Back to Search
Start Over
Targeting the Dopaminergic System in Autoimmunity.
- Source :
-
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology [J Neuroimmune Pharmacol] 2020 Mar; Vol. 15 (1), pp. 57-73. Date of Electronic Publication: 2019 Jan 19. - Publication Year :
- 2020
-
Abstract
- Dopamine has emerged as a fundamental regulator of inflammation. In this regard, it has been shown that dopaminergic signalling pathways are key players promoting homeostasis between the central nervous system and the immune system. Dysregulation in the dopaminergic system affects both innate and adaptive immunity, contributing to the development of numerous autoimmune and inflammatory pathologies. This makes dopamine receptors interesting therapeutic targets for either the development of new treatments or repurposing of already available pharmacological drugs. Dopamine receptors are broadly expressed on different immune cells with multifunctional effects depending on the dopamine concentration available and the pattern of expression of five dopamine receptors displaying different affinities for dopamine. Thus, impaired dopaminergic signalling through different dopamine receptors may result in altered behaviour of immunity, contributing to the development and progression of autoimmune pathologies. In this review we discuss the current evidence involving the dopaminergic system in inflammatory bowel disease, multiple sclerosis and Parkinson's disease. In addition, we summarise and analyse the therapeutic approaches designed to attenuate disease development and progression by targeting the dopaminergic system. Graphical Abstract Targetting the dopaminergic system in autoimmunity. Effector T-cells (Teff) orchestrate inflamamtion involved in autoimmunity, whilst regulatory T-cells (Tregs) suppress Teff activity promoting tolerance to self-constituents. Dopamine has emerged as a key regulator of Teff and Tregs function, thereby dopamine receptors have becoming important therapeutic targets in autoimmune disorders, especially in those affecting the brain and the gut, where dopamine levels strongly change with inflammation.
- Subjects :
- Animals
Autoimmune Diseases immunology
Autoimmunity physiology
Dopamine immunology
Dopamine metabolism
Humans
Inflammatory Bowel Diseases drug therapy
Inflammatory Bowel Diseases immunology
Inflammatory Bowel Diseases metabolism
Multiple Sclerosis drug therapy
Multiple Sclerosis immunology
Multiple Sclerosis metabolism
Parkinson Disease drug therapy
Parkinson Disease immunology
Parkinson Disease metabolism
Receptors, Dopamine immunology
Receptors, Dopamine metabolism
T-Lymphocytes drug effects
T-Lymphocytes immunology
T-Lymphocytes metabolism
Autoimmune Diseases drug therapy
Autoimmune Diseases metabolism
Autoimmunity drug effects
Dopamine Agents administration & dosage
Dopamine Agents metabolism
Drug Delivery Systems trends
Subjects
Details
- Language :
- English
- ISSN :
- 1557-1904
- Volume :
- 15
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 30661214
- Full Text :
- https://doi.org/10.1007/s11481-019-09834-5